1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/56591
Full metadata record
DC FieldValueLanguage
dc.creatorPaula Cella Giacomettopt_BR
dc.creatorMarcello Tortelli Bavarescopt_BR
dc.creatorJuliana Alvares Teodoropt_BR
dc.creatorRicardo Mesquita Camelopt_BR
dc.date.accessioned2023-07-18T16:50:29Z-
dc.date.available2023-07-18T16:50:29Z-
dc.date.issued2021-
dc.citation.volume43pt_BR
dc.citation.spage1pt_BR
dc.citation.epage4pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.htct.2022.10.003pt_BR
dc.identifier.issn2531-1379pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/56591-
dc.description.resumoInherited hemophilia A is a rare bleeding disorder due to absent/reduced activity of the clotting factor VIII (FVIII).1 Therefore, its treatment is based on regular FVIII infusions to prevent (i.e., prophylaxis) or treat (i.e., on demand) bleedings.1 The most impacting complication of this treatment is the development of anti-FVIII antibodies (i.e., inhibitors).1 Inhibitors reduce/abolish the clotting activity of FVIII, rendering the patients with the previous or worse bleeding phenotype, which ultimately leads to increased morbimortality.1 Although bypassing agents (recombinant activated factor VII [rFVIIa] and partially activated prothrombin complex [aPCC]) can be prescribed for both prophylactic and on-demand treatments, the current recommended prophylactic drug in such cases is the humanized bispecific antibody emicizumab.1,2 Emicizumab mimics the clotting effect of FVIII and, since its structure is not similar to the FVIII structure, anti-FVIII inhibitors have no effect on its clotting activity.1,2 There are few reports about the hemostatic effectiveness and safety of this biopharmaceutical on major non-orthopedic surgeries.3, 4, 5 In addition, since the introduction of emicizumab in the armamentarium for hemophilia treatment in Brazil, in 2018, no major surgical procedures have been reported in Brazilian patients on emicizumab prophylaxis. Herein we described a man with severe hemophilia A and high-responding inhibitor under emicizumab prophylaxis who was submitted to open cholecystectomy due to acute-on-chronic calculous cholecystitis. This report was approved by the local Committee on Ethics on Research (May/29/2019). The patient signed the Consent Form before his data was reviewed on the hospital medical files.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIALpt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofHematology, Transfusion and Cell Therapypt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectHemophilia Apt_BR
dc.subjectInhibitorpt_BR
dc.subjectEmicizumabpt_BR
dc.subjectSurgerypt_BR
dc.subjectCholecystectomypt_BR
dc.subject.otherHemofiliapt_BR
dc.subject.otherInibidorespt_BR
dc.subject.otherColecistectomiapt_BR
dc.titleCholecystectomy in a man with hemophilia A and inhibitor on emicizumab prophylaxis: a case reportpt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.sciencedirect.com/science/article/pii/S2531137922014584?via%3Dihubpt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-4023-275Xpt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-3685-1555pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0210-0721pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-9025-0289pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
CholecystectomyinamanwithhemophiliaAand inhibitoronemicizumabprophylaxis Acasereport.pdf455.33 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.